Feasibility and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin plus vinorelbine in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer - A retrospective analysis

Teppei Yamaguchi, Toru Nakanishi, Sumito Isogai, Masamichi Hayashi, Tami Hoshino, Sakurako Uozu, Mariko Morishita, Tomoyuki Minezawa, Mitsushi Okazawa, Kazuyoshi Imaizumi

Research output: Contribution to journalArticle

Abstract

Objective: We evaluated the safety and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin (CDDP) plus vinorelbine (VNR) in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively analyzed patients who received adjuvant chemotherapy after undergoing complete resection of NSCLC at Fujita Health University Hospital between May 2007 and December 2011. The patients were treated with CDDP (40 mg/m2) and VNR (25 mg/m2) on days 1 and 8 every 3 weeks for 4 cycles. We examined the toxicity, compliance with chemotherapy, relapse-free survival (RFS) and overall survival (OS). Results: The grade 3 or 4 hematological toxicities included neutropenia in 29 cases (97%), leukopenia in 18 cases (60%), anemia in 2 cases (7%) and febrile neutropenia in 3 cases (10%). The grade 3 or 4 nonhematological toxicities included infection in 5 cases (17%), transaminase increase in 1 case (3%) and injection site reaction in 1 case (3%). No treatment-related deaths were noted in this study. A total of 24 patients (80%) completed the planned 4 cycles of CDDP plus VNR. The median doses of CDDP and VNR were 320 and 178 mg/m2, respectively. The 1-, 2- and 3-year RFS rates were 82%, 63% and 46%, respectively, while the 1-, 2- and 3-year OS rates were 93%, 89% and 84%, respectively. Conclusions: Postoperative adjuvant chemotherapy consisting of 40 mg/m2 of CDDP and 25 mg/m2 of VNR administered on days 1 and 8 is feasible with acceptable efficacy in Japanese patients with surgically resected stage II and IIIA NSCLC in the daily clinical setting.

Original languageEnglish
Pages (from-to)318-323
Number of pages6
JournalJapanese Journal of Lung Cancer
Volume53
Issue number4
DOIs
Publication statusPublished - 01-12-2013

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Cisplatin
Survival Rate
Recurrence
Febrile Neutropenia
Survival
Leukopenia
Transaminases
Neutropenia
vinorelbine
Anemia
Safety
Drug Therapy
Injections
Health
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Yamaguchi, Teppei ; Nakanishi, Toru ; Isogai, Sumito ; Hayashi, Masamichi ; Hoshino, Tami ; Uozu, Sakurako ; Morishita, Mariko ; Minezawa, Tomoyuki ; Okazawa, Mitsushi ; Imaizumi, Kazuyoshi. / Feasibility and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin plus vinorelbine in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer - A retrospective analysis. In: Japanese Journal of Lung Cancer. 2013 ; Vol. 53, No. 4. pp. 318-323.
@article{372fa6fbb4084318a2d14bd1ac213a57,
title = "Feasibility and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin plus vinorelbine in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer - A retrospective analysis",
abstract = "Objective: We evaluated the safety and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin (CDDP) plus vinorelbine (VNR) in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively analyzed patients who received adjuvant chemotherapy after undergoing complete resection of NSCLC at Fujita Health University Hospital between May 2007 and December 2011. The patients were treated with CDDP (40 mg/m2) and VNR (25 mg/m2) on days 1 and 8 every 3 weeks for 4 cycles. We examined the toxicity, compliance with chemotherapy, relapse-free survival (RFS) and overall survival (OS). Results: The grade 3 or 4 hematological toxicities included neutropenia in 29 cases (97{\%}), leukopenia in 18 cases (60{\%}), anemia in 2 cases (7{\%}) and febrile neutropenia in 3 cases (10{\%}). The grade 3 or 4 nonhematological toxicities included infection in 5 cases (17{\%}), transaminase increase in 1 case (3{\%}) and injection site reaction in 1 case (3{\%}). No treatment-related deaths were noted in this study. A total of 24 patients (80{\%}) completed the planned 4 cycles of CDDP plus VNR. The median doses of CDDP and VNR were 320 and 178 mg/m2, respectively. The 1-, 2- and 3-year RFS rates were 82{\%}, 63{\%} and 46{\%}, respectively, while the 1-, 2- and 3-year OS rates were 93{\%}, 89{\%} and 84{\%}, respectively. Conclusions: Postoperative adjuvant chemotherapy consisting of 40 mg/m2 of CDDP and 25 mg/m2 of VNR administered on days 1 and 8 is feasible with acceptable efficacy in Japanese patients with surgically resected stage II and IIIA NSCLC in the daily clinical setting.",
author = "Teppei Yamaguchi and Toru Nakanishi and Sumito Isogai and Masamichi Hayashi and Tami Hoshino and Sakurako Uozu and Mariko Morishita and Tomoyuki Minezawa and Mitsushi Okazawa and Kazuyoshi Imaizumi",
year = "2013",
month = "12",
day = "1",
doi = "10.2482/haigan.53.318",
language = "English",
volume = "53",
pages = "318--323",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "4",

}

Feasibility and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin plus vinorelbine in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer - A retrospective analysis. / Yamaguchi, Teppei; Nakanishi, Toru; Isogai, Sumito; Hayashi, Masamichi; Hoshino, Tami; Uozu, Sakurako; Morishita, Mariko; Minezawa, Tomoyuki; Okazawa, Mitsushi; Imaizumi, Kazuyoshi.

In: Japanese Journal of Lung Cancer, Vol. 53, No. 4, 01.12.2013, p. 318-323.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Feasibility and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin plus vinorelbine in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer - A retrospective analysis

AU - Yamaguchi, Teppei

AU - Nakanishi, Toru

AU - Isogai, Sumito

AU - Hayashi, Masamichi

AU - Hoshino, Tami

AU - Uozu, Sakurako

AU - Morishita, Mariko

AU - Minezawa, Tomoyuki

AU - Okazawa, Mitsushi

AU - Imaizumi, Kazuyoshi

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Objective: We evaluated the safety and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin (CDDP) plus vinorelbine (VNR) in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively analyzed patients who received adjuvant chemotherapy after undergoing complete resection of NSCLC at Fujita Health University Hospital between May 2007 and December 2011. The patients were treated with CDDP (40 mg/m2) and VNR (25 mg/m2) on days 1 and 8 every 3 weeks for 4 cycles. We examined the toxicity, compliance with chemotherapy, relapse-free survival (RFS) and overall survival (OS). Results: The grade 3 or 4 hematological toxicities included neutropenia in 29 cases (97%), leukopenia in 18 cases (60%), anemia in 2 cases (7%) and febrile neutropenia in 3 cases (10%). The grade 3 or 4 nonhematological toxicities included infection in 5 cases (17%), transaminase increase in 1 case (3%) and injection site reaction in 1 case (3%). No treatment-related deaths were noted in this study. A total of 24 patients (80%) completed the planned 4 cycles of CDDP plus VNR. The median doses of CDDP and VNR were 320 and 178 mg/m2, respectively. The 1-, 2- and 3-year RFS rates were 82%, 63% and 46%, respectively, while the 1-, 2- and 3-year OS rates were 93%, 89% and 84%, respectively. Conclusions: Postoperative adjuvant chemotherapy consisting of 40 mg/m2 of CDDP and 25 mg/m2 of VNR administered on days 1 and 8 is feasible with acceptable efficacy in Japanese patients with surgically resected stage II and IIIA NSCLC in the daily clinical setting.

AB - Objective: We evaluated the safety and efficacy of adjuvant chemotherapy with a split-dose regimen of cisplatin (CDDP) plus vinorelbine (VNR) in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively analyzed patients who received adjuvant chemotherapy after undergoing complete resection of NSCLC at Fujita Health University Hospital between May 2007 and December 2011. The patients were treated with CDDP (40 mg/m2) and VNR (25 mg/m2) on days 1 and 8 every 3 weeks for 4 cycles. We examined the toxicity, compliance with chemotherapy, relapse-free survival (RFS) and overall survival (OS). Results: The grade 3 or 4 hematological toxicities included neutropenia in 29 cases (97%), leukopenia in 18 cases (60%), anemia in 2 cases (7%) and febrile neutropenia in 3 cases (10%). The grade 3 or 4 nonhematological toxicities included infection in 5 cases (17%), transaminase increase in 1 case (3%) and injection site reaction in 1 case (3%). No treatment-related deaths were noted in this study. A total of 24 patients (80%) completed the planned 4 cycles of CDDP plus VNR. The median doses of CDDP and VNR were 320 and 178 mg/m2, respectively. The 1-, 2- and 3-year RFS rates were 82%, 63% and 46%, respectively, while the 1-, 2- and 3-year OS rates were 93%, 89% and 84%, respectively. Conclusions: Postoperative adjuvant chemotherapy consisting of 40 mg/m2 of CDDP and 25 mg/m2 of VNR administered on days 1 and 8 is feasible with acceptable efficacy in Japanese patients with surgically resected stage II and IIIA NSCLC in the daily clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84892752195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892752195&partnerID=8YFLogxK

U2 - 10.2482/haigan.53.318

DO - 10.2482/haigan.53.318

M3 - Article

AN - SCOPUS:84892752195

VL - 53

SP - 318

EP - 323

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 4

ER -